Neoadjuvant therapy for gastroesophageal adenocarcinoma

Table 1 Two neoadjuvant chemotherapy schedules offered for the treatment of resectable gastroesophageal adenocarcinomas

	MAGIC[24]			FNCLCC-FFCD[27]
	ECFn = 250	Surgeryn = 253	P	FPn = 113	Surgeryn = 111	P
Median age, yr (range)	62 (29-85)	62 (23-81)		63 (36-75)	63 (38-75)
Sex, male (%)	82%	76%		85%	82%
Performance status, 0/1	68/32	68/32		74/26	75/25
Gastric ADK (%)	74%	74%		25%	24%
GOJ ADK (%)	26%	26%		75%	76%
Downstaging/downsizing (%)
T1/T2	52%	38%	0.09	42%	32%	0.16
T3/T4	48%	62%		58%	68%
N0/N1	84%	76%	0.01	(N0) 33%	20%	0.54
N2/N3	16%	29%		(N+) 67%	80%
R0 resection rate (%)	79%	70%	0.03	84%	73%	0.04
5-yr overall survival rate (%)	36%	23%	0.009 (HR = 0.75)	38%	24%	0.002 (HR = 0.69)

ADK: Adenocarcinomas; GOJ: Gastro-esophageal junction; ECF: Epirubicin, cisplatin and 5-FU; FP: 5-fluorouracil and cisplatin; MAGIC: Medical research council; FNCLCC-FFCD: Fédération nationale des centres de lutte contre le cancer - fédération française de cancérologie digestive.